Zehra Haider, MD
Is this your author page?
Make it work for you. Your KevinMD author page is one of the highest-ranking results for your name. An enhanced author page turns this page into a premium profile with your photo, biography, affiliations, publications, and links, publishes your accepted articles in 1 to 3 days, includes a listing in Experts by KevinMD, and comes with a guaranteed interview on The Podcast by KevinMD. See an example · See the enhanced author page → Cancel anytime.
Latest articles
Drugs and prescribing
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced to help manage type 2 diabetes. They improve glycemic control and promote weight loss, which we all know are essential for long-term outcomes. In practice, I've seen that their impact goes beyond…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced to help manage type 2 diabetes. They improve glycemic control and promote weight loss, which we all know are essential for long-term outcomes. In practice, I’ve seen that their impact goes beyond these traditional targets. Patients often benefit from cardiovascular protection and kidney improvements, and emerging data show advantages in areas we did not initially anticipate, such as sleep apnea, joint health, …
Read more…
Beyond weight loss: the expanding benefits of GLP-1 receptor agonists
Conditions and diseases
SGLT2 inhibitors have transformed care for people with type 2 diabetes. They not only lower blood sugar but also reduce cardiovascular events and slow the progression of kidney disease. Given these successes, many have asked whether the same benefits extend…
SGLT2 inhibitors have transformed care for people with type 2 diabetes. They not only lower blood sugar but also reduce cardiovascular events and slow the progression of kidney disease. Given these successes, many have asked whether the same benefits extend to people with type 1 diabetes (T1D).
The answer is not straightforward. In T1D, SGLT2 inhibitors remain off-label, and the biggest concern is the increased risk of diabetic ketoacidosis (DKA). Still, …
Read more…
Are SGLT2 inhibitors safe for type 1 diabetes?
Real physician voices, twice a week
Free, and one click to unsubscribe.
